The Affordable Medicines Facility – malaria is an innovative financing mechanism designed to expand access to the most effective treatment for malaria, artemisinin-based combination therapies (ACTs).
The Affordable Medicines Facility – malaria is a new line of business hosted and managed by the Global Fund. Financial support for the initiative will come from UNITAID, the UK Department for International Development (DFID), and potentially other donors. The Roll Back Malaria Partnership will continue in its important role as a partner to the Affordable Medicines Facility – malaria.
The Affordable Medicines Facility – malaria aims to enable countries to increase the provision of affordable ACTs through the public, private and NGO sectors. This will save lives and reduce the use of less-effective treatments to which malaria parasites are becoming increasingly resistant. It will also reduce the use of artemisinin as a single treatment or monotherapy, thereby delaying the onset of resistance to that drug and preserving its effectiveness.
To achieve this aim, the Global Fund, as host and manager of the AMFm, has negotiated with drug manufacturers to reduce the price of ACTs, and to require that sales prices must be the same for both public and private sector first-line buyers. This is the first major achievement of the AMFm. Private importers now pay up to 80 percent less than they did in 2008-2009. The Global Fund pays most of this reduced price (a ‘buyer co-payment’) directly to manufacturers to further lower the cost to eligible first-line buyers of ACTs purchased from manufacturers. This means that first-line buyers only pay the remainder of the sales price for the ACTs. First-line buyers are expected to pass on the highest possible proportion of this price benefit so that patients are able to buy ACTs across the public, private, not-for-profit and for-profit sectors at prices that are less than those of oral artemisinin monotherapies and competitive with the prices of CQ and SP.
AMFm Phase 1 is being implemented through nine pilots in eight countries: Cambodia, Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania (including Zanzibar) and Uganda. Following the Global Fund Board’s decisions on successful applications to Phase 1 in November 2009, grant amendments or new grant agreements have been signed with most AMFm Phase 1 countries and implementation has started in several countries. The first co-paid ACTs were delivered to Ghana and Kenya in August 2010.”.
If you have any questions about Affordable Medicines Facility – malaria, please consult the Frequently Asked Questions or contact the Global Fund at the following address:
Summary Report on co-paid ACTs
Board Approves Integration of AMFm into Core Global Fund Grant Processes (15 November 2012)
São Paulo - Key Speeches and Declarations
$225 million partnership to bring effective malaria drugs to all who need them
Agreements reduce prices of malaria medicines by up to 80 %
ACT Prices for AMFm Transition 2013
[PDF - 230 KB]
Also available in:
AMFm Phase 1 Independent Evaluation: Multi-Country Baseline Report
[PDF - 5 MB]
Background paper: Forum for Africa-based pharmaceutical manufacturers and potential investors. 2011
[PDF - 1 MB]
Economics and financing of universal access to diagnostics: report of consultation
[PDF - 553 KB]
Economics and financing of universal access to diagnostics: Appendix 1
[PDF - 961 KB]
Economics and financing of universal access to diagnostics: Appendix 2
[PDF - 534 KB]
Estimating Benchmarks of Success in the Affordable Medicines Facility - malaria (AMFm) Phase 1
[PDF - 1 MB]
AMFm Phase 1 M&E Technical Framework
[PDF - 828 KB]
[PDF - 543 KB]
Contact | Report Fraud and Abuse | Legal | RSS | Sitemap
© 2013 The Global Fund to Fight AIDS, Tuberculosis and Malaria